Akimoto Y, Ishiyama T, Ueno H, Hino K, Tomoyasu S, Tsuruoka N
Department of Hematology, Showa University School of Medicine, Japan.
Rinsho Ketsueki. 1995 Nov;36(11):1247-51.
Increased levels of soluble interleukin-2 receptor (sIL-2R) have been noted in the sera of patients with various diseases such as adult T cell leukemia, malignant lymphoma and autoimmune diseases. Using an enzyme-linked immunoabsorbent assay, we assessed sIL-2R levels in the sera of 16 patients with multiple myeloma (MM) and 27 normal subjects. There was a significant increase in the levels of sIL-2R in the patients with myeloma (963 +/- 523 U/ml) compared to normal subjects (213 +/- 80 U/ml). The levels of sIL-2R corresponded well with the clinical stage, M-protein, serum IL-6 and serum beta 2 microglobulin levels. Taking the evidence that the CD4/CD8 ratio decreased as the disease worsened into consideration, the increase in the serum sIL-2R levels of the patients with MM is considered to have some correlation with B and T cell activation through various cytokines including IL-6. Furthermore such evidence would support the role of sIL-2R as a disease monitor of MM.
在患有各种疾病（如成人T细胞白血病、恶性淋巴瘤和自身免疫性疾病）的患者血清中，可溶性白细胞介素-2受体（sIL-2R）水平有所升高。我们采用酶联免疫吸附测定法，评估了16例多发性骨髓瘤（MM）患者和27名正常受试者血清中的sIL-2R水平。与正常受试者（213±80 U/ml）相比，骨髓瘤患者的sIL-2R水平显著升高（963±523 U/ml）。sIL-2R水平与临床分期、M蛋白、血清白细胞介素-6和血清β2微球蛋白水平密切相关。考虑到随着疾病恶化CD4/CD8比值降低这一证据，MM患者血清sIL-2R水平的升高被认为与通过包括白细胞介素-6在内的多种细胞因子激活B细胞和T细胞有一定关联。此外，这些证据将支持sIL-2R作为MM疾病监测指标的作用。
